Sign in Register

Drug class

Topical Janus Kinase (JAK) Inhibitors

Topical Janus kinase (JAK) inhibitors are a class of targeted, non-steroidal immunomodulating therapies formulated for direct cutaneous administration. Read more about Topical Janus Kinase (JAK) Inhibitors

2 drugs in this class 2 manufacturers

Advertisement

Related classes & indications

Iron Chelating AgentsOther therapeutic classes · 45 prescription drugs Phosphodiesterase-4 (PDE4) inhibitorsOther therapeutic classes · 20 prescription drugs Chronic Hand EczemaTop indication · 1 prescription drugs

Drugs in Topical Janus Kinase (JAK) Inhibitors

Showing 1–2 of 2 drugs

Filter & compare in the drug finder → Opens the drug finder with Topical Janus Kinase (JAK) Inhibitors preselected. Add indication or manufacturer filters there.

About Topical Janus Kinase (JAK) Inhibitors.

Topical Janus kinase (JAK) inhibitors are a class of targeted, non-steroidal immunomodulating therapies formulated for direct cutaneous administration.

They exert their therapeutic effects by reversibly inhibiting intracellular Janus kinase enzymes (such as JAK1, JAK2, JAK3, or TYK2), thereby disrupting downstream signal transducer and activator of transcription (STAT) signaling pathways that drive pro-inflammatory cytokine activity.

This localized mechanism effectively suppresses cutaneous inflammation, reduces pruritus, and promotes epidermal re-pigmentation or barrier recovery while limiting overall systemic drug exposure.

Clinically, members of this class are utilized primarily in dermatological indications, including atopic dermatitis and nonsegmental vitiligo.